Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Dry Eye · Conjunctivitis, Allergic · ALDX

Aldeyra Therapeutics

Aldeyra Therapeutics trial registry — 35 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US HQ
2004 Founded
14 Employees
Public company Type
ALDX · NYSE Ticker
Company details
Status
Public
HQ
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US
Founded
2004
Employees
14
Programs
26
Drugs
12
Patents
38
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

Aldeyra Therapeutics clinical trials

Registry index of 35 ClinicalTrials.gov studies linked to Aldeyra Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.

Aldeyra Therapeutics trial registry — 35 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Aldeyra Therapeutics.

  1. Reproxalap Ophthalmic Solution (0.25%) QID — Phase 3

    Clinical update

  2. Reproxalap Ophthalmic Solution (0.25%) — Phase 2

    Clinical update

  3. Reproxalap Ophthalmic Solution (0.25%) — Phase 2

    Clinical update

  4. Reproxalap Ophthalmic Solution (0.25%) — Phase 3

    Clinical update

  5. Reproxalap Ophthalmic Solution (0.25%) — Phase 3

    Clinical update

  6. Reproxalap Ophthalmic Solution (0.25%) — Phase 2

    Clinical update

  7. Reproxalap Ophthalmic Solution (0.25%) — Phase 3

    Clinical update

  8. NS2 Ophthalmic Drops (0.5%) — Phase 2

    Clinical update

Trial registry

35 studies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.